Autres langues Monopar Therapeutics Inc.

Actions

MNPR

US61023L2079

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:50:38 16/09/2026			Varia. 5j.	Varia. 1 janv.
103,62 ^USD	-0,68%		-8,10%	+58,16%

19/08	Monopar Therapeutics Inc. annonce la nomination de Jeffrey D. Kent au poste de vice-président exécutif, responsable des affaires médicales, à compter du 1er septembre 2026	CI
13/08	L'action Monopar Therapeutics recule après une dégradation de Cantor Fitzgerald	MT

Autres langues

20/08	Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - the Liver Meeting(R) 2026
19/08	Monopar Therapeutics Inc. Announces Appointment of Jeffrey D. Kent as Executive Vice President, Head of Medical Affairs, Effective September 1, 2026
19/08	Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
13/08	Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald
13/08	Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08	Monopar Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Monopar Therapeutics' Q2 Net Loss Widens
12/08	Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
22/07	Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease
22/07	Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
20/07	Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
30/06	Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation For ALXN1840 For The Treatment Of Wilson Disease
30/06	Monopar Therapeutics Says ALXN1840 Receives FDA Rare Pediatric Disease Designation in Wilson Disease
30/06	Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell 2000 Value Benchmark
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell 3000E Value Benchmark
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell 3000 Value Benchmark
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Small Cap Comp Value Benchmark
29/06	Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell 2500 Value Benchmark
26/06	Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
26/06	Monopar Presents New Analyses of Phase 3 Focus Data At EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with Alxn1840 Versus Standard of Care in Wilson Disease
23/06	Monopar Therapeutics Inc. Elects Nicole Sweeny as Director
01/06	Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
01/06	Monopar Therapeutics Presents Phase 2 Alxn1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients At Easl 2026